Compare DexCom, Inc. (DXCM) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs NICE Ltd — how do they compare? DexCom, Inc. trades at $88.22 (market cap $33.08B), while NICE Ltd trades at $101.98 (market cap $5.99B). The key difference: DexCom, Inc. is far larger — about 5.5× NICE Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| DXCM | NICE | |
|---|---|---|
Market Cap | $33.08B | $5.99B |
Sector | Health | Technology |
52-Week High | $89.53 | $153.44 |
52-Week Low | $54.84 | $83.15 |
Enterprise Value | $32.53B | $5.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.
Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.
NICE stock trades at $101.85, up 4.88% today, showing strong momentum after exceeding Q2 2026 earnings expectations with $2.70 EPS versus $2.63 expected. The company maintains solid fundamentals with 65.12% gross margins and 13.86% net income margin, while technical indicators show bullish momentum with key resistance at $103. Recent partnerships with RingCentral and ESG initiatives highlight strategic growth positioning.
The outlook remains positive with analyst consensus target of $115 suggesting 13% upside potential. Key risks include competitive pressures in customer engagement software and potential margin compression as revenue growth outpaces profit growth. Institutional ownership trends show mixed activity with some firms increasing positions while others trim holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
